Description:
This reagent is a rhesus IgG1 chimeric version of the broadly neutralizing anti-HIV monoclonal antibody 3BNC117, modified to include the LS mutations (M428L and N434S) in the Fc domain. These amino acid substitutions enhance binding to the neonatal Fc receptor (FcRn), thereby significantly extending the serum half-life of the antibody.
Like the wild-type 3BNC117, this LS-modified version binds the CD4 binding site (CD4bs) on the HIV-1 Envelope (Env) glycoprotein, a conserved and vulnerable epitope targeted by many potent bNAbs. The rhesus Fc region ensures appropriate interaction with macaque immune receptors, making this antibody ideally suited for passive transfer and protection studies in nonhuman primates (NHPs).
Key Features:
- LS Mutations (M428L/N434S): Engineered for enhanced FcRn binding and prolonged serum half-life.
- Rhesus IgG1 Fc: Optimized for effector function and Fc receptor interactions in macaque models.
- CD4bs Specificity: Targets a conserved and functionally essential region of HIV-1 Env.
- Broad Utility: Facilitates longer dosing intervals in preclinical HIV intervention studies.
Applications:
- Long-acting passive immunization in rhesus macaques
- Durability and pharmacokinetic studies in NHPs
- Evaluation of HIV cure strategies, including reservoir targeting
- Fc function studies involving extended antibody exposure
Usage Notes:
This LS-modified 3BNC117 variant is particularly well-suited for studies requiring sustained plasma levels of antibody—such as monthly dosing regimens or long-term prevention trials in NHPs. The extended half-life may enhance in vivo duration and reduce the frequency of administrations.
|